Intercept’s NASH Phase III Enrolling Slowly; Gilead Could Gain Ground

As Gilead’s ASK1 inhibitor nears Phase III, Intercept may be plagued by slower-than-expected enrollment of its Phase III trial for Ocaliva. A recent Biomedtracker survey finds liver docs may be more positively inclined toward the Gilead candidate.

Liver

Gilead Sciences Inc.’s announcement at the J.P. Morgan Healthcare Conference that it will take its lead candidate for non-alcoholic steatohepatitis, the apoptosis signal-regulating kinase-1 (ASK1) inhibitor selonsertib, into Phase III soon is shaking up the NASH race.

It’s premature to predict anything approaching a tectonic shift, but Gilead’s announcement opens up the possibility that the virology powerhouse...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Four Chinese Firms Snag Global First-In-Class Approvals In China

 

Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.

Ultragenyx and Mereo Still Confident Despite Setrusumab Slip Up

 
• By 

The osteogenesis imperfecta drug stumbled in a second interim analysis.

Taiho’s Oral, Mutation-Agnostic DMD Candidate Misses Phase III Endpoint

 
• By 

The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.

ProKidney Pins Hopes On Accelerated Approval For Rilparencel

 

After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.

More from R&D

Taiho’s Oral, Mutation-Agnostic DMD Candidate Misses Phase III Endpoint

 
• By 

The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.

ProKidney Pins Hopes On Accelerated Approval For Rilparencel

 

After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.

BREAKING NEWS: Merck & Co. Leaps Into COPD Space With $10bn Verona Buy

 
• By 

The UK firm's chronic obstructive pulmonary drug Ohtuvayre has been enjoying a stellar launch.